Chinese Journal of Cancer Research · 2012 · 25 citations · 24 references
Life SciencesMedicinal ChemistryPharmacologyApoptosisCancer PharmacologyChemotherapyApoptosis In CancerApoptosis PharmacologyApoptosis RegulationApoptotic SignalingCytotoxic ChemotherapyReactive Oxygen SpeciesApoptotic Signaling In CancerCancer Cell ApoptosisCell Cycle InhibitionG1 Phase ArrestG2 Phase ProgressionReactive Oxygen Species GenerationReactive Oxygen Species-induced ApoptosisReactive Oxygen Species-mediated Apoptosis
OBJECTIVE: To examine the apoptotic effect of ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F), a compound isolated from Pteris semipinnata L (PsL), in human lung cancer A549 cells. METHODS: A549 cells were treated with 5F (0-80 μg/ml) for different time periods. Cytotoxicity was examined using a MTT method. Cell cycle was examined using propidium iodide staining. Apoptosis was examined using Hoechst 33258 staining, enzyme-linked immunosorbent assay (ELISA) and caspase-3 activity analysis. Expression of representative apoptosis-related proteins was evaluated by Western blot analysis. Reactive oxygen species (ROS) level was measured using standard protocols. Potential interaction of 5F with cisplatin was also examined. RESULTS: 5F inhibited the proliferation of A549 cells in a concentration- and time-dependent manner. 5F increased the accumulation of cells in sub-G1 phase and arrested the cells in the G2 phase. Exposure to 5F induced morphological changes and DNA fragmentation that are characteristic of apoptosis. The expression of p21 was increased. 5F exposure also increased Bax expression, release of cytochrome c and apoptosis inducing factor (AIF), and activation of caspase-3. 5F significantly sensitized the cells to cisplatin toxicity. Interestingly, treatment with 5F did not increase ROS, but reduced ROS production induced by cisplatin. CONCLUSION: 5F could inhibit the proliferation of A549 cells by arresting the cells in G2 phase and by inducing mitochondrial-mediated apoptosis.
24
Ramaswamy Govindan, Nathan Page, Daniel Morgensztern et al. · Journal of Clinical Oncology · 2006 · 1.9K citations · Full text
cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2
Jean Gautier, Mark J. Solomon, Robert N. Booher et al. · Cell · 1991 · 850 citations
Cisplatin and platinum drugs at the molecular level (Review)
Teni Boulikas, Maria Vougiouka · Oncology Reports · 2003 · 728 citations
Medicine, Oncology, Pharmacology +14
Controlling Tumor Growth by Modulating Endogenous Production of Reactive Oxygen Species
Alexis Laurent, Carole Nicco, Christiane Chéreau et al. · Cancer Research · 2005 · 505 citations · Full text